Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)-Reference-Cited by-同舟云学术

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

Published:2016-05-13 Issue:12 Volume:57 Page:2839-2847
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Moreau Philippe,Weisel Katja C.,Song Kevin W.,Gibson Craig J.,Saunders Owain,Sternas Lars Axel,Hong Kevin,Zaki Mohamed H.,Dimopoulos Meletios A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://tandfonline.com/doi/pdf/10.1080/10428194.2016.1180685

Reference36 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2. Current treatment landscape for relapsed and/or refractory multiple myeloma

3. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

5. Living With Advanced But Stable Multiple Myeloma: A Study of the Symptom Burden and Cumulative Effects of Disease and Intensive (Hematopoietic Stem Cell Transplant-Based) Treatment on Health-Related Quality of Life

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials;Journal of Comparative Effectiveness Research;2024-07

2. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma;Cancers;2022-12-27

3. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects;Current Oncology;2021-01-21

4. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium;Leukemia & Lymphoma;2019-11-20

5. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials;Clinical Lymphoma Myeloma and Leukemia;2019-07